Predicting Recurrence After Surgical Resection for High-Risk Localized Renal Cell Carcinoma: A Radiomics Clinical Integration Approach.

Journal: The Journal of urology
Published Date: Apr 28, 2025

Abstract

PURPOSE: Adjuvant immunotherapy for clear cell renal cell carcinoma (ccRCC) is controversial because of the absence of reliable biomarkers for identifying patients most likely to benefit. The aim of this study was to develop and validate a quantitative radiomics signature (RS) and a radiomics clinical model to identify patients at increased risk of recurrence after surgery among those eligible for adjuvant immunotherapy.

Authors

  • Zine-Eddine Khene
    Department of Urology, University of Rennes, Rennes, France. zineddine.khene@gmail.com.
  • Raj Bhanvadia
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Isamu Tachibana
    Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Prajwal Sharma
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
  • William Graber
    Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Theophile Bertail
    Department of Urology, University of Rennes, Rennes, France.
  • Raphael Fleury
    Department of Urology, University of Rennes, Rennes, France.
  • Renaud de Crevoisier
    Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France.
  • Karim Bensalah
    Department of Urology, Rennes University Hospital, 2, rue Henri Le Guilloux, 35033, Rennes Cedex, France.
  • Yair Lotan
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Vitaly Margulis
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Keywords

External Resources

Popular Topics
Recent Journals